This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

51/100

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

A total of 282 participants were followed for an average of 2.9 years (standard deviation [SD] 1.3 years). For 50% of individuals, loss of independence in IADLs occurred at CDR-SB >4.5 and in BADLs at CDR-SB >11.5. For individuals with a baseline CDR-SB = 2, treatment with lecanemab would extend independence in IADLs for 10 months (95% confidence interval [CI] 4-18 months) and treatment with donanemab in the low/medium tau group would extend independence in IADLs by 13 months (95% CI 6-24 months). Independence in ADLs can be related to CDR-SB and used to demonstrate the effect of AD treatments in extending the time of independent function, a meaningful outcome for patients and their families. Highlights: We estimated time to loss of independence for people with AD dementiaEstimating time to loss of independence can help with clinical decision-makingDisease-modifying treatments for AD dementia can extend independence.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Hartz, S. M., Schindler, S. E., Streitz, M. L., Moulder, K. L., Mozersky, J. T., Wang, G., et al. (2025). Assessing the clinical meaningfulness of slowing CDR‐SB progression with disease‐modifying therapies for Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. https://doi.org/10.1002/trc2.70033

Vancouver

Hartz SM, Schindler SE, Streitz ML, Moulder KL, Mozersky JT, Wang G, et al. Assessing the clinical meaningfulness of slowing CDR‐SB progression with disease‐modifying therapies for Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 2025. doi:10.1002/trc2.70033. PMID: 39949872.

BibTeX

@article{hartz2025-39949872,
  author  = {Hartz, Sarah M. and Schindler, Suzanne Elizabeth and Streitz, Marissa L. and Moulder, Krista L. and Mozersky, Jessica T. and Wang, Guoqiao and Xiong, Chengjie and Morris, John C.},
  title   = {{Assessing the clinical meaningfulness of slowing CDR‐SB progression with disease‐modifying therapies for Alzheimer's disease}},
  journal = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
  year    = {2025},
  doi     = {10.1002/trc2.70033},
  pmid    = {39949872},
  url     = {https://doi.org/10.1002/trc2.70033}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

A total of 282 participants were followed for an average of 2.9 years (standard deviation [SD] 1.3 years).
For 50% of individuals, loss of independence in IADLs occurred at CDR-SB >4.5 and in BADLs at CDR-SB >11.5.
For individuals with a baseline CDR-SB = 2, treatment with lecanemab would extend independence in IADLs for 10 months (95% confidence interval [CI] 4-18 months) and treatment with donanemab in the low/medium tau group would extend independence in IADLs by 13 months (95% CI 6-24 months).
Independence in ADLs can be related to CDR-SB and used to demonstrate the effect of AD treatments in extending the time of independent function, a meaningful outcome for patients and their families.
Highlights: We estimated time to loss of independence for people with AD dementiaEstimating time to loss of independence can help with clinical decision-makingDisease-modifying treatments for AD dementia can extend independence.

Why it matters

For people with a baseline CDR-SB of 2, lecanemab would extend independence in instrumental activities of daily living by 10 months and donanemab in the low/medium tau group by 13 months. This links CDR-SB to loss of independence and shows disease-modifying treatments can extend the time of independent function.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Participants282
Evidence strengthLow

How this study scored 51/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s & Dementia Translational Research & Clinical Interventions)
Journal's citation record	1 / 4	Alzheimer s & Dementia Translational Research & Clinical Interventions: journal h-index 84 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	282 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	3 / 7	Cited 15 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	5.0 citations a year over 3 year(s) since 2025
Impact for its field and year	4 / 6	Cited 9.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 4 other studies in this library
Still being cited	2 / 4	Cited 15 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author John C. Morris: h-index 209 (OpenAlex, whole career)
Institution's track record	2 / 3	Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multicenter collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 39949872)
Free to read	2 / 2	Free to read
Total	51 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Treatments

Also in Treatments

192 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →